FDA Accepts Shionogi’s sNDA for Fetroja in Pediatric Gram-Negative Infections
FLORHAM PARK, N.J., July 16, 2026 Shionogi Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
FLORHAM PARK, N.J., July 16, 2026 Shionogi Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted...
SPAIN, July 1, 2026 Telum Therapeutics announced the successful completion of an €18 million Series A financing round to...
WALTHAM, Mass., June 16, 2026 Innoviva Specialty Therapeutics announced an exclusive distribution and licensing agreement with Dr. Reddy’s Laboratories...
BASEL, Switzerland, April 16, 2026 BioVersys AG has announced a key clinical milestone with the first patient first visit...
